Reset Map4 Results
7171 Rue Frederick Banting Montréal, QC, H4S 1Z9 CanadaDomain Therapeutics NA (DTNA) Inc. specializes in G Protein-Coupled Receptor (GPCR) and Receptor Tyrosine Kinase (RTK) signaling and function. Our BRET-based bioSensAllTM biosensor technology allows for detailed and broad-spectrum signaling profiling of GPCRs, RTKs and their ligands, while leaving these receptors untagged. This technology revolves primarily around the real-time monitoring of receptor proximal events immediately linked to the transmembrane receptor activity, namely heterotrimeric G protein activation and β-arrestin coupling for the GPCRs, and SH2-domain proteins for the RTKs. The GPCR assay brings the unique capacity to quantify the engagement of 14 distinct heterotrimeric G protein subtypes as well as both non-visual β-arrestin isoforms. The RTK assay gives the possibility to follow the recruitment of various SH2-domain proteins and study the complete trafficking of these receptors. Both assays provide a complete and detailed fingerprint of any GPCR / RTK ligand and allow to study the impact of receptor mutations on their signaling. This data is particularly valuable in a screen / early drug development program to select and optimally design your lead compound. Domain Therapeutics applies a multi-string corporate strategy to grow its business through: validation of its technologies through collaborative partnerships with Pharma/Biotechs, generation of an internal pipeline of 1st in class drug candidates for high unmet needs in CNS and oncology, valuation of its preclinical assets through spin-out vehicles, financed by leading investment funds or supported by development-only companies.
BIOPARC 850 Boulevard Sébastien Brant ILLKIRCH-STRASBOURG FranceDomain Therapeutics NA (DTNA) Inc. specializes in G Protein-Coupled Receptor (GPCR) and Receptor Tyrosine Kinase (RTK) signaling and function. Our BRET-based bioSensAllTM biosensor technology allows for detailed and broad-spectrum signaling profiling of GPCRs, RTKs and their ligands, while leaving these receptors untagged. This technology revolves primarily around the real-time monitoring of receptor proximal events immediately linked to the transmembrane receptor activity, namely heterotrimeric G protein activation and β-arrestin coupling for the GPCRs, and SH2-domain proteins for the RTKs. The GPCR assay brings the unique capacity to quantify the engagement of 14 distinct heterotrimeric G protein subtypes as well as both non-visual β-arrestin isoforms. The RTK assay gives the possibility to follow the recruitment of various SH2-domain proteins and study the complete trafficking of these receptors. Both assays provide a complete and detailed fingerprint of any GPCR / RTK ligand and allow to study the impact of receptor mutations on their signaling. This data is particularly valuable in a screen / early drug development program to select and optimally design your lead compound. Domain Therapeutics applies a multi-string corporate strategy to grow its business through: validation of its technologies through collaborative partnerships with Pharma/Biotechs, generation of an internal pipeline of 1st in class drug candidates for high unmet needs in CNS and oncology, valuation of its preclinical assets through spin-out vehicles, financed by leading investment funds or supported by development-only companies.
7171 Rue Frederick-Banting St. Laurent, Quebec, H4S 1Z9 CanadaDomain Therapeutics NA (DTNA) Inc. specializes in G Protein-Coupled Receptor (GPCR) and Receptor Tyrosine Kinase (RTK) signaling and function. Our BRET-based bioSensAllTM biosensor technology allows for detailed and broad-spectrum signaling profiling of GPCRs, RTKs and their ligands, while leaving these receptors untagged. This technology revolves primarily around the real-time monitoring of receptor proximal events immediately linked to the transmembrane receptor activity, namely heterotrimeric G protein activation and β-arrestin coupling for the GPCRs, and SH2-domain proteins for the RTKs. The GPCR assay brings the unique capacity to quantify the engagement of 14 distinct heterotrimeric G protein subtypes as well as both non-visual β-arrestin isoforms. The RTK assay gives the possibility to follow the recruitment of various SH2-domain proteins and study the complete trafficking of these receptors. Both assays provide a complete and detailed fingerprint of any GPCR / RTK ligand and allow to study the impact of receptor mutations on their signaling. This data is particularly valuable in a screen / early drug development program to select and optimally design your lead compound. Domain Therapeutics applies a multi-string corporate strategy to grow its business through: validation of its technologies through collaborative partnerships with Pharma/Biotechs, generation of an internal pipeline of 1st in class drug candidates for high unmet needs in CNS and oncology, valuation of its preclinical assets through spin-out vehicles, financed by leading investment funds or supported by development-only companies.
BIOPARC 850 Boulevard Sébastien Brant 67400 ILLKIRCH-STRASBOURG FranceDomain Therapeutics NA (DTNA) Inc. specializes in G Protein-Coupled Receptor (GPCR) and Receptor Tyrosine Kinase (RTK) signaling and function. Our BRET-based bioSensAllTM biosensor technology allows for detailed and broad-spectrum signaling profiling of GPCRs, RTKs and their ligands, while leaving these receptors untagged. This technology revolves primarily around the real-time monitoring of receptor proximal events immediately linked to the transmembrane receptor activity, namely heterotrimeric G protein activation and β-arrestin coupling for the GPCRs, and SH2-domain proteins for the RTKs. The GPCR assay brings the unique capacity to quantify the engagement of 14 distinct heterotrimeric G protein subtypes as well as both non-visual β-arrestin isoforms. The RTK assay gives the possibility to follow the recruitment of various SH2-domain proteins and study the complete trafficking of these receptors. Both assays provide a complete and detailed fingerprint of any GPCR / RTK ligand and allow to study the impact of receptor mutations on their signaling. This data is particularly valuable in a screen / early drug development program to select and optimally design your lead compound. Domain Therapeutics applies a multi-string corporate strategy to grow its business through: validation of its technologies through collaborative partnerships with Pharma/Biotechs, generation of an internal pipeline of 1st in class drug candidates for high unmet needs in CNS and oncology, valuation of its preclinical assets through spin-out vehicles, financed by leading investment funds or supported by development-only companies.
Site Information
The Contract Research Map is owned and maintained by Scientist.com. It was created to help researchers in the life sciences identify and connect with contract research organizations (CROs) based on geography. Updated nightly, this map features all of the available CROs within our network, so you can order services with a few clicks. Click on a specific country, scroll on the map itself or type into the search bar at the top—there are many ways to find the location and suppliers that you’re looking for. From Argentina to New Zealand, use this map to connect with a CRO near you.
We believe that every researcher across the world should be able to connect with the thousands of global CROs that exist and have the opportunity to work together. Like many industries,the life science supply chain has been disrupted over the last year. But there are many other circumstances such as international customs regulations or sensitive shipping times that create limitations around which countries are feasible to partner with. Sometimes, finding a CRO based in a country that best suits your research needs is imperative. We hope this contract research map allows you to find the right partner in the right place at the right time.
Have questions or feedback? We’d love to help. You can find our FAQs and contact information on the Learn more page.
Interested in connecting with one or more of the contract research organizations listed on this map? By clicking on the company’s name, you will be directed to their supplier profile on the Scientist.com marketplace. Once you set up a marketplace account you can start the ordering process immediately.
What is Scientist.com?
Scientist.com is the world's largest enterprise marketplace for outsourced R&D services. It saves time and money and provides access to innovation while maintaining compliance with an organization’s procurement policies.
How can I use Scientist.com?
Scientist.com has built private, enterprise marketplaces from 24 of the 30 largest pharmaceutical companies, 80+ biotech companies, the US National Institutes of Health (NIH) and numerous other pharma and biotech companies. If you are employed by one of these organizations, you can log in to get started today. If you are unsure about how to get started, you can email our team at support@scientist.com or go to our website www.scientist.comto speak to someone via our live chat.
Why should I place my order through Scientist.com?
Scientist.com is a highly efficient enterprise-wide outsourcing marketplace that makes it possible for research organizations to save time and money, access innovation and ensure compliance. It utilizes a universal legal agreement and AI technologies to enable research like never before. See how comparing proposals and getting 1-on-1 support from our Research Concierge® team will enable you to place more research today.
How do I get my organization listed on the map?
If your CRO isn’t showing up on the map, then please be sure your company profile is up to date in Scientist.com’s Backoffice. After logging in, click the Your Company button in the navigation at the top, and then select the Locations tab.
Information about my organization is incorrect, how do I fix it?
Head over to backoffice.scientist.com to update your supplier profile and information. It may take up to two business days for the updates to be reflected on the map.